ART-27.13 is a Small Molecule owned by Artelo Biosciences, and is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing.

NEO-1940 (AZD-1940) is a mixed CB1/CB2 cannabinoid receptor agonist. Cannabinoid receptors are G-protein coupled receptors. The drug candidate by limiting cell proliferation induces tumour-selective cell death in cancer patients.

The revenue for ART-27.13 is expected to reach a total of $41m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ART-27.13 NPV Report.

ART-27.13 was originated by AstraZeneca and is currently owned by Artelo Biosciences.

ART-27.13 Overview

ART-27.13 (NEO-1940, AZD-1940) is under development for the treatment of cancer related anorexia. The drug candidate is an benzimidazole derivative and it is administered orally. It acts on cannabinoid (CB1) type 1 and type 2 receptor. It was also under development for the treatment of post-operative pain, multimodal supportive care in weight loss, appetite loss, pain, nausea, vomiting, anxiety, and insomnia in cancer patients.

Artelo Biosciences Overview

Artelo Biosciences is a biopharmaceutical company. The company develops and commercializes proprietary therapeutics targeting the endocannabinoid system. Artelo Biosciences is a biopharmaceutical company. The company develops and commercializes proprietary therapeutics targeting the endocannabinoid system.

Quick View – ART-27.13

Report Segments
  • Innovator
Drug Name
  • ART-27.13
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Oncology
  • Toxicology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.